Pfizer(PFE) - 2024 Q3 - Quarterly Results

Exhibit 99 Pfizer Reports Strong Third-Quarter 2024 Results And Raises 2024 Guidance ▪ Third-Quarter Performance Driven by Focused Commercial Execution and Robust Double-Digit Revenue Growth Across Product Portfolio (1) (2) ▪ Raises Full-Year 2024 Revenue Guidance to a Range of $61.0 to $64.0 Billion and Raises Adjusted Diluted EPS Guidance to a Range of $2.75 to $2.95 ▪ Third-Quarter 2024 Revenues of $17.7 Billion, Representing 32% Year-over-Year Operational Growth – Excluding Contributions from Paxlovid a ...